Abbott CEO expects high demand for antibody tests even after approved COVID-19 vaccine

July 16 (Reuters) - Abbott Laboratories expects to see higher demand for serology and antibody testing for the new coronavirus, even after a vaccine becomes available, Chief Executive Officer Rober Ford said on a post-earnings conference call on Thursday.

The company, which has two antibody tests authorized for emergency use in the United States, said testing volumes in its underlying diagnostics unit, excluding COVID-19 tests, also rebounded to about 90% of pre-COVID levels by the end of the second quarter. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)

07/16/2020 14:23

News, Photo and Web Search